News & Events

News Releases

August 8, 2008

Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate

January 5, 2010

Icon Bioscience Initiates Phase 2/3 Pivotal Clinical Study of Novel Ophthalmic Drug Candidate

May 4, 2010

Icon to Present Clinical Data on Verisome Technology in Cystoid Macular Edema at the ARVO Annual Meeting

December 7, 2011

Icon Appoints Murahashi Vice President, Clinical Development

January 3, 2013

Icon’s Melphalan Intraocular Injection Granted U.S. Orphan Drug Designation For the Treatment of Retinoblastoma

Share
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089
Copyright © 2013 Icon Bioscience, Inc. · Optimization by MME · Log in